RecruitingNCT06270043

Focal Therapy for Localized Prostate Cancer

A Prospective Registry and Longitudinal Study of Patients Undergoing Focal Therapy for Localized Prostate Cancer


Sponsor

University of California, San Diego

Enrollment

500 participants

Start Date

Feb 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care.


Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria3

  • Subject has elected or already undergone focal therapy as their standard of care treatment method and declined alternative treatment (active surveillance, radical prostatectomy, and radiation therapy)
  • PSA ≤ 20
  • Ability to complete informed consent form

Exclusion Criteria2

  • Contraindication to follow-up multi parametric MRI or prostate biopsy
  • Unable to tolerate general or regional anesthesia

Interventions

PROCEDUREFocal Therapy

Focal ablation of prostate cancer using different modalities. These modalities include: * Cryoablation or Cryotherapy * Irreversible Electroporation - Nanoknife * High Intensity Frequency Ultrasound - FocalOne * Transurethral Ultrasound Ablation - TULSA - PRO


Locations(1)

University of California, San Diego

La Jolla, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06270043


Related Trials